Stockscreener 앱 받기
1.42
5.33%
-0.08
시장 영업 전:
1.38
-0.04
-2.82%
전일 마감가:
$1.50
열려 있는:
$1.5
하루 거래량:
2.09M
Relative Volume:
0.24
시가총액:
$9.80M
수익:
-
순이익/손실:
$-9.62M
주가수익비율:
-0.2977
EPS:
-4.77
순현금흐름:
$-7.93M
1주 성능:
-8.39%
1개월 성능:
+75.31%
6개월 성능:
+72.71%
1년 성능:
+10.08%
1일 변동 폭
$1.36
$1.55
1주일 범위
$1.36
$1.7099
52주 변동 폭
$0.58
$3.80
Hoth Therapeutics Inc Stock (HOTH) Company Profile
명칭
Hoth Therapeutics Inc
전화
(646)756-2997
주소
590 MADISON AVENUE, NEW YORK, NY
HOTH을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
HOTH
Hoth Therapeutics Inc
|
1.42 | 9.80M | 0 | -9.62M | -7.93M | -4.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Hoth Therapeutics Inc Stock (HOTH) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2019-10-15 | 개시 | The Benchmark Company | Speculative Buy |
Hoth Therapeutics Inc 주식(HOTH)의 최신 뉴스
Hoth Therapeutics expands cancer drug patent portfolio - MSN
HOTH Stock Soars as Skin Toxicity Study in Cancer Patients Meets Goal - MSN
Hoth Therapeutics Acquires New Patent Applications - Contract Pharma
Hoth Therapeutics Expands Cancer Drug Patent Portfolio, Strengthens HT-001 Development Strategy - StockTitan
Hoth Therapeutics to Attend Sequire Investor Summit January 21-23, 2025 - PR Newswire
Hoth Therapeutics’ (HOTH) “Buy” Rating Reiterated at D. Boral Capital - Defense World
Biotech Stock Roundup: NMRA Plunges on Study Failure, HOTH, VIR Soar on Study Data & More - MSN
Shares Of This Micro Cap More Than Doubled Today - MSN
3 Penny Stocks to Watch Now, 1/9/25 - TipRanks
Hoth Therapeutics maintains strong cash position, no offering plans By Investing.com - Investing.com Nigeria
Hoth Therapeutics Shares Recover; Company Has No Plans for Offering - MarketWatch
Hoth Therapeutics maintains strong cash position, no offering plans - Investing.com
Hoth Therapeutics Responds to Market Rumors and Shareholder Inquiries - PR Newswire
S&P 500 E-Mini (ESM23) Quote - The Globe and Mail
Hoth Therapeutics’ Stock Triples On Promising Cancer Trial Data for Skin Toxicity Therapy: Retail’s Excited - Asianet Newsable
Dow Jones Transportations Average (DOWT) QuotePress Release - The Globe and Mail
Dow Jones Global (DOWG) QuotePress Release - The Globe and Mail
Hoth reports 100% success in cancer skin toxicity trial By Investing.com - Investing.com South Africa
Hoth Therapeutics up over 218% on dermatology breakthrough for cancer patients - Mugglehead
Hoth Therapeutics stock hits 52-week high at $1.73 By Investing.com - Investing.com Australia
S&P 500 ESG (ESG) QuotePress Release - The Globe and Mail
PHLX Euro FX (XDE) QuotePress Release - The Globe and Mail
TSX Composite Low Volatility (TXLV) QuotePress Release - The Globe and Mail
Hoth Therapeutics Soars 215% on Breakthrough Cancer Treatment Success - Yahoo Finance
Why Hoth Therapeutics Inc Stock Might Make Sense If Bought Today - Stocks Register
Stock market news: Hoth Therapeutics +184.32%, DatChat +79.85% among top gainers during mid day trading - Business Upturn
Stock market news: SPI Energy saw rise of 276.74% while Hoth Therapeutics surged by 186.73% during mid day trading - Business Upturn
Nasdaq Down 1.5%; RPM Posts Upbeat Results - Benzinga
Hoth’s phase IIa derma data in cancer patients propels its stock - BioWorld Online
Why Is Hoth Therapeutics Stock Flying Higher On Tuesday? - Benzinga
Hoth Therapeutics Shares Hit 52-Week High on Positive Data for Cancer Treatment - MarketWatch
Stock market today: XTI Aerospace surged by 108.52% while ACELYRIN posted fall of 38.68% in early trading - Business Upturn
Dow Surges Over 100 Points; US Trade Deficit Widens In November - Benzinga
Hoth Therapeutics stock hits 52-week high at $1.73 - Investing.com
Hoth reports 100% success in cancer skin toxicity trial - Investing.com
Hoth Therapeutics Achieves Breakthrough in Phase 2a Trial: HT-001 Delivers 100% Success in Combating Cancer Treatment Skin Toxicities - PR Newswire
Cero Therapeutics to effect 1-for-100 reverse stock split - Yahoo Finance
VA Enters Into Development Partnership with Hoth Therapeutics - The Presidential Prayer Team
Viking Therapeutics, Inc. (VKTX) Advances While Market Declines: Some Information for Investors - Yahoo Finance
Hoth acquires license to technology developed by the VA and Emory University - BioWorld Online
Hoth licenses patents to develop anti-obesity treatments - MSN
EGFR Inhibitors-Induced Skin Disorders Market to Show Remarkable Growth Trends from 2023 to 2032, DelveInsight Reports | Lutris Pharma, Hoth Therapeutics, TWi Biotechnology - Barchart
Hoth Therapeutics Enters Partnership with the Department of Veterans Affairs to Develop Obesity Treatment - Longview News-Journal
Is Sarepta Therapeutics, Inc. (SRPT) the Best Performing Biotech Stock in 2024? - Yahoo Finance
Hoth Therapeutics Announces Expansion of Clinical Sites for HT-001 Phase 2a Trial - The Eastern Progress Online
Hoth Therapeutics Inc (HOTH) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.81%
자본화:
|
볼륨(24시간):